[go: up one dir, main page]

DK2379581T3 - Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander - Google Patents

Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander

Info

Publication number
DK2379581T3
DK2379581T3 DK10787815.9T DK10787815T DK2379581T3 DK 2379581 T3 DK2379581 T3 DK 2379581T3 DK 10787815 T DK10787815 T DK 10787815T DK 2379581 T3 DK2379581 T3 DK 2379581T3
Authority
DK
Denmark
Prior art keywords
multimerically
ligands
ability
link
modified ubiquitin
Prior art date
Application number
DK10787815.9T
Other languages
English (en)
Inventor
Anja Kunert
Joerg Nerkamp
Arnd Steuernagel
Markus Fiedler
Erik Fiedler
Thomas Goettler
Original Assignee
Scil Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh filed Critical Scil Proteins Gmbh
Application granted granted Critical
Publication of DK2379581T3 publication Critical patent/DK2379581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
DK10787815.9T 2009-12-14 2010-12-14 Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander DK2379581T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09179147 2009-12-14
EP10162264 2010-05-07
EP10186980 2010-10-08
PCT/EP2010/069674 WO2011073214A2 (en) 2009-12-14 2010-12-14 A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands

Publications (1)

Publication Number Publication Date
DK2379581T3 true DK2379581T3 (da) 2014-01-06

Family

ID=43648750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10787815.9T DK2379581T3 (da) 2009-12-14 2010-12-14 Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander

Country Status (14)

Country Link
US (3) US8921304B2 (da)
EP (3) EP2367843B1 (da)
JP (3) JP5667207B2 (da)
KR (2) KR101436222B1 (da)
CN (2) CN102753568B (da)
AU (2) AU2010332938B2 (da)
BR (2) BR112012014417B1 (da)
CA (3) CA2782093A1 (da)
DK (1) DK2379581T3 (da)
ES (1) ES2441803T3 (da)
IL (2) IL219754A (da)
PL (1) PL2379581T3 (da)
RU (2) RU2556820C2 (da)
WO (3) WO2011073209A1 (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) * 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US6639684B1 (en) * 2000-09-13 2003-10-28 Nextengine, Inc. Digitizer using intensity gradient to image features of three-dimensional objects
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
WO2012171541A1 (en) * 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US9492572B2 (en) * 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012172054A1 (en) * 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
PT2594588E (pt) 2011-11-16 2014-08-28 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PT3553084T (pt) 2011-11-16 2023-02-17 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
SG10201802054TA (en) 2011-11-16 2018-05-30 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
HUE032648T2 (en) 2011-11-16 2017-10-30 Sphingotec Gmbh Adrenomedullin assays and procedures for determining the concentration of mature adrenomedullin
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
NZ629283A (en) * 2012-03-16 2016-04-29 Covagen Ag Novel binding molecules with antitumoral activity
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
US20150183846A1 (en) * 2012-06-13 2015-07-02 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
DK2904403T3 (da) 2012-10-02 2018-07-16 Sphingotec Gmbh Fremgangsmåde til diagnosticering eller overvågning af nyrefunktion eller diagnosticering af nyredysfunktion
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
US20150346222A1 (en) 2013-01-08 2015-12-03 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
US10598674B2 (en) 2013-03-20 2020-03-24 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
CN103834664B (zh) * 2014-03-27 2016-05-04 吉林大学 重组表皮生长因子egf及其制备方法
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
EP3677285B1 (en) * 2014-08-04 2023-12-13 Case Western Reserve University Targeting peptides for detecting prostate cancer
EP3002589A1 (en) 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
EP3253795B1 (en) 2015-02-06 2019-04-17 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
JP6841765B2 (ja) 2015-04-24 2021-03-10 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 慢性腎疾患の発症のリスクを予測するための方法
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013129A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Her2 binding proteins based on di-ubiquitin muteins
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
JP6256445B2 (ja) * 2015-09-30 2018-01-10 ダイキン工業株式会社 Ｉｃカートリッジ及環境調整装置
LU92906B1 (en) 2015-12-14 2017-06-20 Luxembourg Inst Science & Tech List Method for enzymatically modifying the tri-dimensional structure of a protein
EP3854817A1 (en) 2016-04-21 2021-07-28 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and therapeutic methods
CN105958923B (zh) * 2016-04-22 2018-06-19 宁波大智机械科技股份有限公司 一种太阳能光伏板的屋顶瓦片连接结构
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
EP3482208B1 (en) 2016-07-08 2023-04-12 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure
AU2017311541B2 (en) 2016-08-11 2020-08-13 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
MX2019007107A (es) 2016-12-16 2019-10-21 Adrenomed Ag Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
CN106905435B (zh) * 2017-03-13 2020-04-10 武汉海沙百得生物技术有限公司 一种制备基于蛋白a突变体的结合蛋白的方法
CA3065415A1 (en) 2017-05-30 2018-12-06 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
CA3076691A1 (en) 2017-09-25 2019-03-28 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
EP3698134A1 (en) 2017-10-18 2020-08-26 AdrenoMed AG Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
AU2018356370A1 (en) 2017-10-24 2020-04-09 Sphingotec Gmbh Selenoprotein P for prediction of a first cardiovascular event
CN111542548B (zh) 2017-10-25 2024-07-30 4Teen4制药有限公司 针对并结合于特异性dpp3表位的dpp3结合剂及其在预防或治疗与氧化应激相关的疾病/急性病状中的用途
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
AU2019219071A1 (en) 2018-02-08 2020-07-30 Sphingotec Gmbh Adrenomedullin (ADM) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
KR20190135393A (ko) * 2018-05-28 2019-12-06 주식회사 원진바이오테크놀로지 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
AU2019409572B2 (en) * 2018-12-18 2022-11-24 Navigo Proteins Gmbh Novel FOLR1 specific binding proteins for cancer diagnosis and treatment
AU2019408553A1 (en) 2018-12-20 2021-06-17 Sphingotec Gmbh Selenoprotein P in heart failure
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
JP7498971B2 (ja) * 2019-04-10 2024-06-13 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング がん診断及び治療のための新規ｐｓｍａ特異的結合タンパク質
EP4014049A1 (en) 2019-08-15 2022-06-22 sphingotec GmbH A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
CN114556100A (zh) 2019-08-30 2022-05-27 4Teen4制药有限公司 用于治疗休克的疗法指引和/或疗法监测
IL293078A (en) * 2019-11-27 2022-07-01 Onegene Biotechnology Inc A polymer of multi-functional, multi-specific biomolecules with prolonged in vivo duration
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
WO2021170880A2 (en) 2020-02-27 2021-09-02 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
JP2023515042A (ja) 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト ショックの治療若しくは予防において使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
BR112022015215A2 (pt) 2020-02-27 2022-10-11 4TEEN4 Pharmaceuticals GmbH Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
CN114854739B (zh) * 2021-02-04 2024-02-06 中国科学院苏州纳米技术与纳米仿生研究所 一种细胞外基质及其制备方法和应用
WO2022263648A1 (en) 2021-06-18 2022-12-22 Sphingotec Gmbh A method for predicting sepsis and septic shock
WO2023275099A1 (en) 2021-06-29 2023-01-05 Berysol Gmbh Composite biomarker for the identification of selenium deficiency in a bodily fluid
JP2025509304A (ja) 2022-03-15 2025-04-11 アドレノメト アクチェンゲゼルシャフト 抗アドレノメデュリン（ａｄｍ）抗体又は抗ａｄｍ抗体フラグメントの安定な水性製剤
JP2025525059A (ja) 2022-07-29 2025-08-01 アドレノメト アクチェンゲゼルシャフト ショックの治療又は予防に使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
EP4562430A1 (en) 2022-07-29 2025-06-04 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
CA3266214A1 (en) * 2022-10-24 2024-05-02 Navigo Proteins Gmbh NEW PROTEINS WITH HIGH BINDING AFFINITY TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
WO2024194276A1 (en) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025068313A1 (en) 2023-09-25 2025-04-03 Sphingotec Gmbh A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
FR2761688A1 (fr) 1997-04-02 1998-10-09 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
WO1998054312A1 (en) 1997-05-28 1998-12-03 Babraham Institute Ribosome complexes as selection particles for in vitro display and evolution of proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US6799121B2 (en) 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20110179531A1 (en) 2000-05-09 2011-07-21 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040043386A1 (en) 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
US20040076965A1 (en) 2002-10-16 2004-04-22 Bosserhoff Anja Katrin MIA-2 protein
US20100212037A1 (en) 2002-10-16 2010-08-19 Anja Katrin Bosserhoff Mia-2 protein
DE10256669B4 (de) 2002-12-04 2006-03-09 Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle Gemisch mindestens zweier Fusionsproteine sowie ihre Herstellung und Verwendung
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
AU2003250972A1 (en) 2003-07-14 2005-01-28 Mattex Leisure Industries Artificial turf filament and artificial turf system
CA2544764A1 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
WO2005059131A2 (en) 2003-12-11 2005-06-30 Yale University Protein binding miniature proteins and uses thereof
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
DE602006012667D1 (de) 2005-05-11 2010-04-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
DE502005009389D1 (de) 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
MX2008013575A (es) 2006-05-08 2008-11-04 Philogen Spa Citoquinas dirigidas a anticuerpos para terapia.
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법

Also Published As

Publication number Publication date
AU2010332938A1 (en) 2012-05-10
JP5749733B2 (ja) 2015-07-15
AU2010332932B2 (en) 2013-01-17
RU2556820C2 (ru) 2015-07-20
EP2367843A1 (en) 2011-09-28
JP5667207B2 (ja) 2015-02-12
PL2379581T3 (pl) 2014-03-31
CA2782093A1 (en) 2011-06-23
US20130157878A1 (en) 2013-06-20
WO2011073214A2 (en) 2011-06-23
WO2011073214A3 (en) 2011-08-11
US8921304B2 (en) 2014-12-30
JP2013513375A (ja) 2013-04-22
KR20110111304A (ko) 2011-10-10
CN102753568A (zh) 2012-10-24
EP2513138A1 (en) 2012-10-24
CA2778872A1 (en) 2011-06-23
EP2513138B1 (en) 2014-10-01
JP2013513376A (ja) 2013-04-22
KR20120110171A (ko) 2012-10-09
EP2379581B1 (en) 2013-10-09
EP2379581A2 (en) 2011-10-26
CN102753568B (zh) 2014-08-20
WO2011073208A9 (en) 2011-08-04
JP2012523227A (ja) 2012-10-04
RU2012115491A (ru) 2013-10-27
KR101353677B1 (ko) 2014-02-12
EP2367843B1 (en) 2014-10-08
RU2012114662A (ru) 2013-10-20
ES2441803T3 (es) 2014-02-06
IL219755A (en) 2017-09-28
CN102753569A (zh) 2012-10-24
RU2553333C2 (ru) 2015-06-10
BR112012014417A2 (pt) 2017-01-10
US20120301393A1 (en) 2012-11-29
IL219754A (en) 2014-12-31
BR112012014194A2 (pt) 2017-01-10
BR112012014417B1 (pt) 2021-11-09
WO2011073209A1 (en) 2011-06-23
AU2010332932A1 (en) 2012-05-10
US8748351B2 (en) 2014-06-10
CA2778871A1 (en) 2011-06-23
IL219755A0 (en) 2012-07-31
IL219754A0 (en) 2012-07-31
CA2778872C (en) 2015-06-02
WO2011073208A1 (en) 2011-06-23
AU2010332938B2 (en) 2012-12-20
KR101436222B1 (ko) 2014-09-01
US20130011334A1 (en) 2013-01-10
CA2778871C (en) 2017-08-01

Similar Documents

Publication Publication Date Title
DK2379581T3 (da) Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander
DK2723771T3 (da) Serumalbuminbindende proteiner
BR112013014278A2 (pt) proteínas de ligação a tnf-a
DK2643349T3 (da) Designede repeat-proteiner, der binder til serumalbumin
EP3715356C0 (en) PROCESS FOR PURIFYING POLYPEPTIDES
DK2784157T3 (da) Designfremgangsmåde til et rna-bindende protein under anvendelse af ppr-motiv og anvendelse deraf
CO7020862A2 (es) Proteinas de unión al antígeno cd27l
DK2651249T3 (da) Fremgangsmåde til fremstilling af en valleproteinsammensætning med reduceret astringens
DK2794907T3 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK3178490T3 (da) RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
BRPI0920749A2 (pt) proteínas de ligação de antagonista multialvo cd86
BR112012001681A2 (pt) domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
DK2977455T3 (da) Fremgangsmåde til langfragmentaflæsnings-sekventering
DK2742135T4 (da) Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
DK2370814T3 (da) Fremgangsmåde til diagnosticering af allergiske reaktioner
DK2606061T3 (da) Bindingsproteiner til hepcidin
HUE033063T2 (hu) IL-1 kötõ fehérjék
EP2781599A4 (en) NUCLEIC ACID FRAGMENT BINDING TO A TARGET PROTEIN
DK3714788T3 (da) Fremgangsmåde til fremstilling af forbedrede analytsensorer
DK2780375T3 (da) Bindingsmolekyler til bcma og cd3
DK3543333T3 (da) Fremgangsmåde til screening af alfa-amylaser
DK2411048T3 (da) Adjuvanterende meningokok-faktor h-bindingsprotein
DK2531526T3 (da) Fremgangsmåde til opnåelse af antistoffer
EP2417455A4 (en) IMPROVED METHODS FOR PERFORMING ASSAYS
DK2358661T3 (da) Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl